The United States Department of Defense (DoD) has awarded Barrow Neurological Institute an $840,000 grant to repurpose an existing class of drugs to target a specific molecular pathway that scientists have recently linked to ALS and other neurodegenerative diseases.
The two-year Therapeutic Idea Award—led by David Medina, PhD, an assistant professor in the Bowser Laboratory in the Department of Translational Neuroscience at Barrow—aims to increase our understanding of the role of m6A dysregulation in ALS and determine whether targeting this dysregulation with small-molecule drugs can reduce progression of the disease.